Lab21 reinforces “UK molecular Dx leadership” with Delphic buy
This article was originally published in Clinica
Executive Summary
Lab21 has consolidated its presence in the UK molecular diagnostics market by purchasing bankrupt Delphic Diagnostics from its administrators BDO. Delphic (London, UK) is a laboratory offering pharmacology, virology, therapeutic drug monitoring and specialist clinical trial services to the pharma industry. The laboratory also has specific expertise in HIV and hepatitis, personalised medicine and companion diagnostics. Cambridge, UK-based Lab21 said that the deal would contribute “substantial” sales in 2010 and be accretive to its earnings from early next year. Financial details of the acquisition were not revealed. This deal is part of Lab21’s buy-and-build strategy and is the firm’s third acquisition this year, following deals for Biotec Laboratories in March and Plasmatec Laboratory Products in May (www.clinica.co.uk, May 20 2009).